Biodexa Pharmaceuticals Plc (BDRX)

[Volcano]

$BDRX The 12-month results from the Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis (FAP) were presented at the InSIGHT 2024 meeting in Barcelona. Here are the key findings:

Reduction in Polyp Burden: There was a significant reduction in the total number of polyps compared to the baseline measurements.
Non-Progression Rates: The treatment showed high rates of non-progression, meaning it effectively prevented the growth and development of new polyps.
Safety Profile: eRapa was generally well-tolerated, with only a few serious adverse events reported, which were manageable and did not outweigh the benefits.
These results are promising for the potential use of eRapa in managing FAP, offering hope for a condition that currently has limited treatment options.
.